Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are female
- People aged between 18 and 40 years old
- People who are pregnant with a single baby, at a stage of pregnancy between 28 weeks and 0 days, and 41 weeks and 0 days, at the time of giving consent to join the trial
- People who are having a caesarean section, whether planned in advance or decided during labour
Who may not be able to join:
- People who have been hospitalised with a diagnosis of preeclampsia (a pregnancy-related condition involving high blood pressure) and are being treated with blood pressure-lowering medications or magnesium sulfate
- People whose baby has been found to have a major physical structural abnormality or a chromosomal condition
- People who are having a caesarean section due to the placenta separating early (placental abruption) or due to bleeding complications
- People whose stage of pregnancy at the time of enrolment (delivery) is not between 36 weeks and 0 days, and 41 weeks and 0 days (confirm with trial site, as this differs from the consent stage requirement listed above)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sathish Kumar, PhD, University of Wisconsin, Madison
Phone: 608-890-3345
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Quantify the vascular AT2R expression and vascular function in placental and omental vascular arteries in both preeclamptic and controlled pregnancies.; To test if ex-vivo treatment of AT2R agonists reverses the endothelial dysfunction and improves vasoconstriction in the preeclamptic vessels.; To test AT2R mediated mechanisms on endothelial derived hyperpolarizing factor, nitric oxide and prostacyclin pathway of vascular relaxation to examine AT2's role in vaso-relaxation and AT2R mediated vasoconstrictor pathway will be defined.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.